{
  "id": 19404861,
  "title": "PepGen soars on promising early data for muscular dystrophy drug",
  "url": "https://urgent.news/2026/11/10/pepgen-soars-on-promising-early-data-for-muscular-dystrophy-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-10T21:48:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/pepgen-myotonic-dystrophy-dm1-drug-results-freedom/874249/"
  },
  "original_language": "en",
  "account": null,
  "summary": "While from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}